Efficacy, individual effectiveness, and population effectiveness in substance abuse treatment

Current psychiatry reports

Volumn 2, Issue 6, 2000, Pages 505-507

  Woody, George E ^a   Muñoz, Alvaro ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADDICTION; ARTICLE; EPIDEMIOLOGY; HUMAN; INFORMATION PROCESSING; STATISTICS; TREATMENT OUTCOME; UNITED STATES;

BIAS (EPIDEMIOLOGY); DATA COLLECTION; HUMANS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; UNITED STATES;

EID: 0034566186     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-000-0009-3     Document Type: Article

References (9)

1. 1. A Muñoz SJ Gange LP Jacobson 2000 Distinguishing efficacy, individual effectiveness and population effectiveness of therapies AIDS 14 734 736 10.1097/00002030-200004140-00020 Muñoz A, Gange SJ, Jacobson LP: Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS 2000, 14:734–736.
2. 2. S Lamb MR Greenlick D McCarty 1998 Bridging the Gap Between Practice and Research: Forging Partnerships with Community-Based Drug and Alcohol Treatment Institute of Medicine Press Washington, DC 2.Lamb S, Greenlick MR, McCarty D: Bridging the Gap Between Practice and Research: Forging Partnerships with Community-Based Drug and Alcohol Treatment. Washington, DC: Institute of Medicine Press; 1998.
3. 3. A Muñoz D Hoover 1995 Use of cohort studies for evaluating AIDS therapies DM Finkelstein DA Schoenfeld In AIDS clinical trials Wiley New York 423 446 Muñoz A, Hoover D: Use of cohort studies for evaluating AIDS therapies. In In AIDS clinical trials. Edited by Finkelstein DM, Schoenfeld DA. New York: Wiley; 1995:423–446.
4. 4. SM Hammer P Yeni 1998 Antiretroviral therapy: where are we? AIDS 12 suppl A S181 S188 9633001 Hammer SM, Yeni P: Antiretroviral therapy: where are we? AIDS 1998, 12 (suppl A):S181-S188.
5. 5. AN Phillips S Graber JM Iassic 1999 Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials AIDS 13 2075 2082 10546860 10.1097/00002030-199910220-00010 1:CAS:528:DyaK1MXnsVSitbg%3D Phillips AN, Graber S, Iassic JM, et al.: Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. AIDS 1999, 13:2075–2082.
6. 6. R Detels A Muñoz G McFarlane 1998 Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HiV infection duration JAMA 280 1497 1503 9809730 10.1001/jama.280.17.1497 1:STN:280:DyaK1M%2FisFKjsA%3D%3D 6.Detels R, Muñoz A, McFarlane G, et al.: Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HiV infection duration. JAMA 1998, 280:1497–1503.
7. 7. S Chen TH Wagner P Barnett 2000 Expenditures for substance abuse treatment in the Department of Veterans Affairs: 1993–1999. Report from the Health Economics Resource Center and the Center for Health Care Evaluation VA Palo Alto Health Care System Menlo Park Chen S, Wagner TH, Barnett P: Expenditures for substance abuse treatment in the Department of Veterans Affairs: 1993–1999. Report from the Health Economics Resource Center and the Center for Health Care Evaluation. Menlo Park: VA Palo Alto Health Care System; 2000.
8. 8. 8.Memorandum From Committee Minority Staff, To Senator John D. Rockefeller IV. Ranking Minority Report On Minority Staff Review Of VA Programs For Veterans With Special Needs. Committee On Veterans Affairs, US Senate. July 27, 1999.
9. 9. Ahdieh L, Gange S, Greenblatt R, et al.: Selection by indication of potent antiretroviral therapy usage in a large cohort of HIV-infected women. Am J Epidemiol 2000, in press.